Hansa Biopharma AB (publ) (STO:HNSA)
45.14
-2.18 (-4.61%)
Nov 20, 2026, 5:29 PM CET
Hansa Biopharma AB Revenue
Hansa Biopharma AB had revenue of 142.99M SEK in the quarter ending September 30, 2026, with 364.18% growth. This brings the company's total for the last twelve months to 301.64M, up 68.88% year-over-year. In the year 2025, Hansa Biopharma AB had annual revenue of 222.27M with 29.74% growth. That makes Hansa Biopharma AB the 31,538th largest company in the world by revenue and 410th in Sweden.
Revenue (ttm)
301.64M
Revenue Growth
+68.88%
P/S Ratio
15.23
Revenue / Employee
2.72M
Employees
131
Market Cap
4.59B
Revenue by Geography
- Europe (Ex Sweden) 202.28M 91.0%
- North America 14.09M 6.3%
- Rest of The World 5.90M 2.7%
Fiscal year ended Dec 31, 2025 See the full Hansa Biopharma AB breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 222.27M | 50.95M | 29.74% |
| Dec 31, 2024 | 171.32M | 37.22M | 27.76% |
| Dec 31, 2023 | 134.09M | -20.43M | -13.22% |
| Dec 31, 2022 | 154.53M | 120.65M | 356.12% |
| Dec 31, 2021 | 33.88M | 27.78M | 455.56% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BioArctic AB | 1.00B |
| Saniona AB | 424.56M |
| Genovis AB (publ.) | 145.23M |
| Oncopeptides AB | 103.50M |
| Egetis Therapeutics AB | 70.00M |
| Medivir AB | 8.51M |
| Vicore Pharma Holding AB | 3.83M |
| Flerie AB | 2.60M |
Hansa Biopharma AB News
- 5 days ago - Hansa Biopharma AB Transcript: Jefferies Global Healthcare Conference - Transcripts
- 10 days ago - Hansa's Q3 Loss Widens To SEK 17 Mln As Idefirix Market Expands To Australia - Nasdaq
- 11 days ago - Hansa Biopharma AB Earnings Call Transcript: Q3 2026 - Transcripts
- 11 days ago - Hansa Biopharma AB Quarterly report: Q3 2026 - Filings
- 11 days ago - Hansa Biopharma AB Slides: Q3 2026 - Filings
- 11 days ago - Hansa Biopharma Reports Third Quarter and Interim Year to Date 2026 Financial Results - PRNewsWire
- 19 days ago - Hansa Biopharma AB Slides: Corporate presentation - Filings
- 4 weeks ago - Hansa Biopharma announces positive Idefirix PAES results presented in the High-Impact Clinical Trials session at ASN Kidney Week - PRNewsWire